DOI QR코드

DOI QR Code

코자 정(로자탄 칼륨 50 mg)에 대한 로자르탄 정의 생물학적동등성

Bioequivalence of LosartanTM Tablet to CozzarTM Tablet (Losartan Kalium 50 mg)

  • 발행 : 2006.04.20

초록

The purpose of the present study was to evaluate the bioequivalence of two losartan tablets, $Cozaar^{TM}$ tablet (MSD Korea. Co., Ltd., Seoul, Korea, reference drug) and $Losartan^{TM}$ tablet (DaeWon Pharm. Co., Ltd., Korea, test drug), according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty-four healthy male Korean volunteers received two tablets at the losartan kalium dose of 100 mg in a $2\;{\time}\;2$ crossover study. There was a one-week washout period between the doses. Plasma concentrations of losartan were monitored by an LC-MS/MS for over a period of 12 hr after the administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 12 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Cozaar^{TM}/Losartan^{TM}$ were $log\;0.97{\sim}log\;1.12\;and\;log\;0.93{\sim}log\;1.23$, respectively. These values were within the acceptable bioequivalence intervals of $log\;0.80{\sim}log\;1.25$. Taken together, our study demonstrated the bioequivalence of $Cozaar^{TM}$ and $Losartan^TM$ with respect to the rate and extent of absorption.

키워드

참고문헌

  1. 한국임상약학회 편집실, 새로운 고혈압 치료제 Losartan에 대하여, 한국임상약학회지, 7, 91-95 (1997)
  2. 식품의약품안전청 고시 제 2002-60호(2002. 11. 22), 생물학적동등성시험기준
  3. 식품의약품안전청 고시 제 1999-67호(2000. 01. 04), 의약품임상시험관리기준
  4. A.A. Pedro, T.W. Gehr, D.F. Brophy and D.A. Sica, The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. J. Clin. Pharmacol., 40; 389-395 (2000) https://doi.org/10.1177/00912700022009099
  5. Don Farthing, Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate, J. chromatography., 704, 374-378 (1997) https://doi.org/10.1016/S0378-4347(97)00489-1
  6. J.J. Tamimi, I.I. Salem, S. Mahmood Alam, Q. Zaman, R. Dham, Comparative pharmacokinetics of two tablet formulations of Losartan: bioequivalence assessment, Biopharm. Drug Dispos., 26, 205-210 (2005) https://doi.org/10.1002/bdd.448
  7. Michelle Polinko, Kerry Riffel, Hengchang Song, Man-Wal Lo, Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/ tandem mass spectrometry, J. Pharm. Biomed. Anal., 33, 73-84 (2003) https://doi.org/10.1016/S0731-7085(03)00348-0